Amylin Pharmaceuticals Elects Karin Eastham to Board of Directors
September 28 2005 - 5:16PM
PR Newswire (US)
SAN DIEGO, Sept. 28 /PRNewswire-FirstCall/ -- Amylin
Pharmaceuticals, Inc. (NASDAQ:AMLN) today announced that Karin
Eastham has been elected to the company's board of directors
effective immediately. Ms. Eastham will serve on Amylin's audit
committee. "We are very excited to welcome Karin to the Amylin
team," said Ginger L. Graham, President and CEO of Amylin
Pharmaceuticals. "Her extensive financial and operations management
experience in the life sciences industry will be a great asset to
our Board." Ms. Eastham has over 25 years experience in financial
and operations management, primarily in life sciences companies.
She currently serves as Executive Vice President and Chief
Operating Officer, and as a member of the Board of Trustees of the
Burnham Institute for Medical Research, a non-profit corporation,
engaged in basic biomedical research and the home to three research
centers -- a Cancer Center, the Del E. Webb Center for Neuroscience
and Aging and a Center for research on Infectious and Inflammatory
Diseases. From April 1999 to May 2004, Ms. Eastham served as Senior
Vice President, Finance, Chief Financial Officer, and Secretary of
Diversa Corporation, where she led the company's IPO, raising over
$200 MM. She previously held similar positions with CombiChem,
Inc., a computational chemistry company, and Cytel Corporation, a
biopharmaceutical company. Ms. Eastham also held several positions,
including Vice President, Finance, at Boehringer Mannheim
Corporation, from 1976 to 1988. Ms. Eastham also serves as a
director for Tercica, Inc. and Illumina, Inc, public biotechnology
companies, and SGX Pharmaceuticals, Inc. and Cyntellect, Inc.
private biotechnology companies. She also serves on the Board of
UCSD's Athena Program. Ms. Eastham received a B.S. and an M.B.A.
from Indiana University and is a Certified Public Accountant and a
Certified Director. Amylin Pharmaceuticals is a biopharmaceutical
company committed to improving lives through the discovery,
development and commercialization of innovative medicines.
DATASOURCE: Amylin Pharmaceuticals, Inc. CONTACT: Alice Bahner,
Executive Director, Investor Relations of Amylin Pharmaceuticals,
Inc., +1-858-552-2200, ext. 7272 Web site: http://www.amylin.com/
Copyright
Amylin Pharmaceuticals, Inc. (MM) (NASDAQ:AMLN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Amylin Pharmaceuticals, Inc. (MM) (NASDAQ:AMLN)
Historical Stock Chart
From Jul 2023 to Jul 2024